Olatorepatide clinical trials
Olatorepatide is named as an intervention in 4 current clinical trials in our USA and China registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Regeneron Pharmaceuticals (2). The most-studied condition is Overweight or Obesity. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Olatorepatide works
All drug targets →- OverweightPhase 2
- Obesity disorderPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068153, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14425, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Olatorepatide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Olatorepatide
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808 · Overweight or Obesity
|
Phase 2 | Recruiting | Regeneron Pharmaceuticals | USA |
|
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
NCT07156500 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Phase 3 | Not yet open | Jiangsu Hansoh Pharmaceutical Co., Ltd | China |
|
A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Phase 3 | Not yet open | Jiangsu Hansoh Pharmaceutical Co., Ltd | China |
|
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086 · Overweight or Obesity
|
Phase 2 | Active, closed | Regeneron Pharmaceuticals | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Olatorepatide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Olatorepatide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or Obesity without Diabetes (RISE-1)
2025-524861-26-00 · Nutritional and Metabolic Diseases
|
Phase 3 | Authorised | Regeneron Pharmaceuticals Inc | Romania, Poland, Hungary + 2 more |
Conditions studied with Olatorepatide
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in China | 2 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Olatorepatide trials
How many clinical trials are testing Olatorepatide?
4 current trials in our USA and China registers name Olatorepatide (also registered as HS-20094) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Olatorepatide trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Olatorepatide clinical trials?
Regeneron Pharmaceuticals (2) and Jiangsu Hansoh Pharmaceutical Co., Ltd (2). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Olatorepatide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Olatorepatide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Olatorepatide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.